Novel insights to enhance therapeutics with acyclovir in the management of herpes simplex encephalitis.

Simple item page
dc.contributor.authorAssis, Maria Silvia Gurgel
dc.contributor.authorPedrosa, Taciane Cristina Fernandes
dc.contributor.authorMoraes, Fernanda Segurasse de
dc.contributor.authorCaldeira, Tamires Guedes
dc.contributor.authorPereira, Gislaine Ribeiro
dc.contributor.authorSouza, Jacqueline de
dc.contributor.authorRuela, Andre Luís Morais
dc.date.accessioned2022-11-04T18:03:58Z
dc.date.available2022-11-04T18:03:58Z
dc.date.issued2021pt_BR
dc.description.abstractAcyclovir is an antiviral drug poorly absorbed in the gastrointestinal tract due to its hydrophilicity, with low oral bioavailability (~20%). Although acyclovir is prescribed in the management of herpes simplex encephalitis (HSE), the disease has a poor prognosis, particularly if the treatment is delayed, reaching mortality rates of 70% if left untreated. Thus, high acyclovir doses are administered by intravenous (IV) infusion, usually at a dosage of 10 mg kg1 8-hourly in adults with normal renal function. However, the mortality related to HSE treated with acyclovir remains high (~20%) and permanent sequelae are commonly reported after 1 year (~50%). This review analyzed clinical trials following IV acyclovir administration. Novel insights aiming to improve drug bioavailability were reviewed, including acyclovir or its prodrugs, leading to the systemic distribution of the drug or drug targeting. Much research effort has been made to improve antiviral therapy, searching for delivery systems increasing acyclovir bioavailability by non-invasive pathways, such as oral and nasal pathways, or parenterally administered nanotechnology-based systems leading to drug targeting. Nanocarriers administered by non-invasive pathways represent feasible alternatives to treat HSE, even though not be industrially manufactured yet.pt_BR
dc.identifier.citationASSIS, M. S. G. et al. Novel insights to enhance therapeutics with acyclovir in the management of herpes simplex encephalitis. Journal of Pharmaceutical Sciences, v. 110, p. 1557-1571, 2021. Disponível em: <https://www.sciencedirect.com/science/article/abs/pii/S0022354921000083>. Acesso em: 11 out. 2022.pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.xphs.2021.01.003pt_BR
dc.identifier.issn0022-3549
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/15748
dc.identifier.uri2https://www.sciencedirect.com/science/article/abs/pii/S0022354921000083pt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectAbsorption enhancerpt_BR
dc.subjectBioavailabilitypt_BR
dc.subjectClinical trialpt_BR
dc.subjectDrug delivery systempt_BR
dc.subjectDrug targetingpt_BR
dc.titleNovel insights to enhance therapeutics with acyclovir in the management of herpes simplex encephalitis.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_NovelInsigtsEnhace.pdf
Size:
1.82 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEFAR - Artigos publicados em periódicos